EUCTR2007-003250-29-SE进行中（未招募）不适用
A randomised, placebo-controlled, multi-centre study on the efficacy of Niccine, a vaccine for nicotine, in smoking relapse prevention, assessed in abstinent, adult smokers.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Cigarette smokers, smoking on average at least 10 cigarettes per day, has fewer than three months of abstinence in the past year and is motivated to quit.
- •2.Men or women, 25 to 50 years of age (inclusive).
- •3.Women of childbearing capacity must use a reliable contraceptive method, e.g. the double barrier method, an intra-uterine device or oral contraceptive.
- •4.Positive for exhaled carbon monoxide (CO), >5 ppm.
- •5.Healthy and with normal findings in the pre-study physical examination (as judged by the Investigator)
- •6.Has signed the Informed Consent Form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnant and lactating female
- •2.Previous treatment with any nicotine vaccine
- •3.Vaccination with any other vaccine product from four weeks before first dose or planned vaccination until four weeks after the last vaccination with the investgational product.
- •4.Vaccination with any other medicinal product containing TT within two years prior to enrolment.
- •5.Concurrent use of any drug that may have a negative effect on the immune system (as judged by the investigator)
- •6.Use of antidepressant or antipsychotic drugs within six months prior to enrolment in the study
- •7.Concurrent use of any other nicotine containing product than cigarettes
- •8.Current diagnosis or a history of repeated depressive episodes or of anxiety disorders or psychosis.
- •9.Clinical diagnosis of moderate to severe asthma or COPD or emphysema.
- •10.Unstable heart disease (as judged by the Investigator).
- •11.Use of any smoking cessation drugs within six months of enrolment in the study.
- •12.Known hyper reactivity to previous vaccinations with TT.
- •13.Known or suspected allergy or hypersensitivity to any of the components in the investigational or reference products.
- •14.Suspected abuse or misuse of alcohol or any of the drugs tested for during screening.
- •15.Diseases with immunological etiology, e.g. autoimmune disorders.
- •16.History of cancer.
- •17.Positive serology for HIV and/or Hepatitis B and/or Hepatitis C.
- •18.Participation in another clinical study within three months prior to enrolment or during the present study.
- •19.If the Investigator, for any other reason, assesses that the Subject should not be included (e.g. planned travel, expected low compliance, expected withdrawal).
研究者
相似试验
进行中（未招募）
不适用
A randomised, placebo-controlled, multi-centre study on the efficacy of Niccine, a vaccine for nicotine, in smoking relapse prevention, assessed in abstinent, adult smokers.The intended indication for the drug under investigation is smoking relapse prevention. Tobacco smoking has been identified as the single largest preventable cause of morbidity and premature death in the developed world. The prevalence of smoking range from about 20 to 50 per cent in the developed countries and from a global perspective, tobacco smoking continues to increase. The study will be performed in smokers.MedDRA version: 9.1Level: LLTClassification code 10056478Term: Nicotine addictionEUCTR2007-003250-29-DKIndependent Pharmaceutica AB360
进行中（未招募）
1 期
A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400mcg administered once-daily in the morning via DISKUS™ dry-powder inhaler) compared with salmeterol (50mcg administered twice-daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD.Chronic Obstructive Pulmonary DiseaseEUCTR2006-004033-15-NLGlaxoSmithKline Research and Development Limited
进行中（未招募）
1 期
A study of SBC-102 (enzyme replacement therapy) in patients with lysosomal acid lipase deficiencyysosomal Acid Lipase DeficiencyMedDRA version: 20.0Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850EUCTR2011-002750-31-PLAlexion Pharmaceuticals, Inc.66
进行中（未招募）
1 期
A study of SBC-102 (enzyme replacement therapy) in patients with lysosomal acid lipase deficiencyEUCTR2011-002750-31-CZAlexion Pharmaceuticals, Inc.66
进行中（未招募）
1 期
A study of SBC-102 (enzyme replacement therapy) in patients with lysosomal acid lipase deficiencyysosomal Acid Lipase DeficiencyMedDRA version: 14.1Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850EUCTR2011-002750-31-ITSynageva BioPharma Corporation66